Please assess the completion status of the following clinical trial:

Trial Title: Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Living in one of the study villages~* Aged 2 years and above~* Able and willing to provide informed consent~Exclusion Criteria:~* Signs of active leprosy (\*)~* Signs of active pulmonary tuberculosis (cough ≥2 weeks duration) (\*)~* Having received Rifampicin within the last 24 months (\*)~(\*) These people may still be included for yearly leprosy screening, but will be excluded to receive PEP

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No PEP (Type: NO_INTERVENTION): No PEP will be distributed
- Household PEP (Type: OTHER): PEP will be given to all household contacts of an incident leprosy patient
- PEP 100m (Type: EXPERIMENTAL): PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
- PEP 100m + positive for anti-PGL-I IgM Ab (Type: OTHER): PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)

Based on this trial design, predict the completion outcome and termination type (if applicable).